DSM-Firmenich stock enters US sunscreen market after BEMT approval
Published on 11/13/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUS Sunscreen Market Opens
- The FDA approved bemotrizinol, also known as BEMT, in June 2026.
- Early U.S. products from Neutrogena and other manufacturers are reaching store shelves.
- Safety studies involving more than 500 patients found nearly undetectable skin absorption and no irritation or allergic reactions in short-term use.
The U.S. Food and Drug Administration approved bemotrizinol, also known as BEMT, in June 2026, and the first sunscreens containing the ingredient are now reaching American stores. The development creates a new commercial reference point for DSM-Firmenich stock as the group remains associated with the ingredient's research and supply chain.
The Associated Press report published by WSVN said the FDA approval opened the U.S. market to a chemical sunscreen that has long been used in Europe and other regions. Neutrogena and other manufacturers are among the first companies bringing products with BEMT to consumers.
Why BEMT Matters
BEMT is designed to provide broad-spectrum protection against both UVA and UVB radiation in a single chemical ingredient. The AP report said this addresses a formulation gap in the U.S., where manufacturers previously needed several ingredients to achieve the same combination of protection.
The regulatory decision also rests on a substantial safety review. FDA assessors examined studies involving more than 500 patients conducted by Dutch manufacturer DSM Nutritional Products. The reported absorption levels were nearly undetectable, while short-term daily-use studies found no irritation or allergic reactions. The agency classified BEMT as generally recognized as safe and effective.
For investors, the immediate commercial question is not the approval alone but the pace at which sunscreen brands convert the regulatory change into recurring product demand. The outcome will depend on customer launches, consumer adoption and the contribution of the ingredient to beauty-related sales. Environmental questions remain relevant as well: the AP report said longer-term research is still needed on BEMT's effect on coral reefs.
DSM-Firmenich stock traded at 105.58 euros on Lang & Schwarz at 09:50 CET on Friday, November 13, 2026.
DSM-Firmenich market facts
- Company: DSM-Firmenich AG
- ISIN: CH1216478797
- Trading venue: Lang & Schwarz
- Price: 105.58 euros at 09:50 CET on November 13, 2026
European investors are also watching the AEX market environment as the region's listed chemical and consumer-goods companies respond to changing demand.
